Table 2

Risk of prostate cancer among male users of H2 blockers in GHC relative to the general population of western Washington State, 1977–1996

ObservedExpectedSIR95% CI
All users403535.30.80.7–0.8
Time since cohort entry (mo)
  0–114773.00.60.5–0.9
 12–59176230.10.80.7–0.9
 60–119130167.30.80.6–0.9
120+5064.90.80.6–1.0
By type(s) of H2 blocker used
Cimetidine only191271.70.70.6–0.8
Time since cohort entry (mo)
  0–111833.80.50.3–0.8
 12–5992109.40.80.7–1.0
 60–1195491.00.60.4–0.8
120+2737.50.70.5–1.0
Cimetidine and other151180.20.80.7–1.0
Time since cohort entry (mo)
  0–111317.60.70.4–1.3
 12–595071.80.70.5–0.9
 60–1196564.01.00.8–1.3
120+2326.70.90.5–1.3
Other only6183.40.70.6–0.9
Time since cohort entry (mo)
  0–111621.60.70.4–1.2
 12–593448.90.70.5–1.0
 60–1191112.30.90.4–1.6
120+00.700.0–5.6a
  • a One-sided 97.5% CI.